论文部分内容阅读
目的:观察艾塞那肽联合二甲双胍治疗2型糖尿病患者的临床疗效。方法:选取绍兴县中心医院内分泌科诊治的88例糖尿病患者,入选患者均为2型糖尿病,且单用二甲双胍治疗效果不佳。随机分为对照组和观察组,每组44例。对照组在原有的二甲双胍治疗基础上,同时给予吡格列酮治疗;观察组在原有的二甲双胍治疗基础上,同时给予艾塞那肽治疗。结果:治疗前,两组患者的空腹血糖(FBG)、餐后2小时血糖(PBG)和糖化血红蛋白(HbA1c)指标比较,未见明显差异,无统计学意义(P>0.05),有可比性。治疗后,两组患者的FBG、PBG和HbA1c指标均有不同程度的降低,与之前的指标比较,有明显的差异,差异有统计学意义(P<0.05);组间比较,观察组患者的FBG、PBG和HbA1c指标比对照组低,有明显的差异,差异有统计学意义(P<0.05)。对照组患者不良反应发生率为18.2%(8/44)高于观察组患者不良反应发生率15.9%(7/44),但差异无统计学意义(P>0.05)。结论:艾塞那肽联合二甲双胍治疗2型糖尿病患者的临床效果比吡格列酮联合二甲双胍的临床效果好,未见严重不良反应,安全性好,值得临床推广应用。
Objective: To observe the clinical efficacy of exenatide combined with metformin in type 2 diabetic patients. Methods: A total of 88 diabetic patients diagnosed and treated in Department of Endocrinology, Central Hospital of Shaoxing County were enrolled in this study. Type 2 diabetes mellitus was selected as the treatment group. Metformin alone was ineffective. Randomly divided into control group and observation group, 44 cases in each group. The control group was treated with pioglitazone on the basis of the original metformin treatment. The observation group was treated with exenatide on the basis of the original metformin treatment. Results: Before treatment, the fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG) and HbA1c were not significantly different between the two groups (P> 0.05) . After treatment, the FBG, PBG and HbA1c indexes of both groups decreased to some extent, compared with the previous indicators, there was a significant difference (P <0.05); between the two groups, the patients in the observation group FBG, PBG and HbA1c indicators lower than the control group, there were significant differences, the difference was statistically significant (P <0.05). The incidence of adverse reactions was 18.2% (8/44) in the control group and 15.9% (7/44) in the observation group, but the difference was not statistically significant (P> 0.05). Conclusion: The clinical efficacy of exenatide combined with metformin in the treatment of type 2 diabetes mellitus is better than that of pioglitazone combined with metformin, no serious adverse reactions, good safety and worthy of clinical application.